You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT JAMA
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 290 No. 17, November 5, 2003 TABLE OF CONTENTS
  JAMA
  •  Online Features
  Medical News & Perspectives
 This Article
 •Full text
 •PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on Web of Science (12)
 •Contact me when this article is cited
 Related Content
 •Similar articles in JAMA
 Topic Collections
 •Cardiovascular System
 •Cardiovascular Disease/ Myocardial Infarction
 •Drug Therapy
 •Drug Therapy, Other
 •Alert me on articles by topic
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Expanding Statin Use to Help More At-Risk Patients Is Causing Financial Heartburn

Mike Mitka

JAMA. 2003;290:2243-2245.

Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Vienna, Austria—Last year, findings from the Heart Protection Study, a 20 500-patient clinical trial in the United Kingdom, showed that adding a statin (simvastatin) to existing treatment regimens for high-risk patients substantially reduced the rates of heart attack and stroke, even among those with cholesterol levels considered to be normal or low (Lancet. 2002;360:7-22). The researchers estimated that implementing the study's major finding—that statins should be prescribed for patients based on risk, not just cholesterol level—would more than triple the number of individuals benefiting from the drugs. Principal investigator Rory Collins, MD, reportedly predicted that statins would eventually become "the new aspirin."

Like aspirin, statins have the potential to reduce heart attack and stroke. But unlike aspirin, which costs pennies per day, statins carry a heftier price tag—about $2 to $3 a day in the United States down to about $1 a day for generics entering some . . . [Full Text of this Article]



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Does Simvastatin Cause More Myotoxicity Compared with Other Statins?
Backes et al.
The Annals of Pharmacotherapy 2009;43:2012-2020.
ABSTRACT | FULL TEXT  

Red Yeast Rice for Dyslipidemia in Statin-Intolerant Patients: A Randomized Trial
Becker et al.
ANN INTERN MED 2009;150:830-839.
ABSTRACT | FULL TEXT  

Narrative Review: Statin-Related Myopathy
Joy and Hegele
ANN INTERN MED 2009;150:858-868.
ABSTRACT | FULL TEXT  

A 39-year-old woman with hypercholesterolemia.
Mittleman
JAMA 2006;296:319-326.
ABSTRACT | FULL TEXT  

Effectiveness and efficiency of different guidelines on statin treatment for preventing deaths from coronary heart disease: modelling study
Manuel et al.
BMJ 2006;332:1419.
ABSTRACT | FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2003 American Medical Association. All Rights Reserved.